Company intelligence / Profile preview

Cytocast

Ownership: Private
Development stage: Preclinical

Overview

Cytocast has developed an advanced cell simulation platform that uses AI, high-performance computing, and multi-omics data integration to model billions of molecular interactions per second. The platform predicts drug candidate side effects, optimizes treatments, identifies new targets or repurposing opportunities, and supports precision medicine initiatives. No direct clinical results as the company does not develop its own therapeutics but enables R&D for others.

Therapeutic areas: Other
Modalities: Small moleculeBiologicMonoclonal antibody
Industry: Drug Discovery Services

Beyond the preview

Go deeper on Cytocast.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytocast.

Explore the full profile